Raghani Neha R, Chorawala Mehul R, Parekh Kavya, Sharma Anvesha, Alsaidan Omar Awad, Alam Prawez, Fareed Mohammad, Prajapati Bhupendra
Department of Pharmacology and Pharmacy Practice, Saraswati Institute of Pharmaceutical Sciences, Gandhinagar, Gujarat, 382355, India.
Department of Pharmacology and Pharmacy Practice, L. M. College of Pharmacy, Opp. Gujarat University, Ahmedabad, Gujarat, 380009, India.
Med Oncol. 2025 May 4;42(6):193. doi: 10.1007/s12032-025-02752-y.
Cervical cancer (CC) remains a significant global health burden, particularly in low- and middle-income countries, where access to effective screening and treatment is limited. Despite advancements in conventional therapies, such as surgery, chemotherapy, and radiotherapy, challenges related to late-stage diagnosis, treatment resistance, and disease recurrence persist. The emergence of microRNAs (miRNAs) as key regulators of gene expression has revolutionized cancer diagnostics and therapeutics. Exosomal miRNAs, in particular, have garnered attention due to their stability, detectability in bodily fluids, and pivotal roles in tumor progression, metastasis, and immune modulation. This review provides a comprehensive overview of the role of exosomal miRNAs in the theranostic landscape of CC. We explore their involvement in disease pathogenesis, highlighting their potential as minimally invasive diagnostic biomarkers for early detection and disease monitoring. Furthermore, we examine their utility in therapeutic strategies, including miRNA-mediated drug delivery systems and miRNA-targeted interventions to overcome chemoresistance. Integrating exosomal miRNA profiling with current diagnostic modalities could enhance screening sensitivity and specificity, while miRNA-based therapies offer novel avenues to improve treatment efficacy. This review discusses recent advancements in miRNA research, current challenges in clinical translation, and future perspectives on leveraging exosomal miRNAs for personalized CC care.
宫颈癌（CC）仍然是一项重大的全球健康负担，在低收入和中等收入国家尤其如此，这些国家获得有效筛查和治疗的机会有限。尽管传统疗法（如手术、化疗和放疗）取得了进展，但与晚期诊断、治疗耐药性和疾病复发相关的挑战依然存在。微小RNA（miRNA）作为基因表达的关键调节因子的出现，彻底改变了癌症的诊断和治疗方法。特别是外泌体miRNA，因其稳定性、在体液中的可检测性以及在肿瘤进展、转移和免疫调节中的关键作用而受到关注。本综述全面概述了外泌体miRNA在宫颈癌诊疗领域中的作用。我们探讨它们在疾病发病机制中的作用，强调它们作为用于早期检测和疾病监测的微创诊断生物标志物的潜力。此外，我们研究它们在治疗策略中的效用，包括miRNA介导的药物递送系统和针对miRNA的干预措施以克服化疗耐药性。将外泌体miRNA分析与当前诊断方法相结合可提高筛查的敏感性和特异性，而基于miRNA的疗法为提高治疗效果提供了新途径。本综述讨论了miRNA研究的最新进展、临床转化中的当前挑战以及利用外泌体miRNA实现宫颈癌个性化护理的未来前景。
